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Mycobacterium tuberculosis (MTB) continues to predominate the cause of morbidity, and mortality in the developing world. The
disease aﬀects all the organ systems, and presents in various pathologic disease states. We report an uncommon manifestation of
this rather common infectious disease in a 19-year-old male. Immune-mediated thrombocytopenia occurring as a consequence of
the tuberculosis infection itself is an exceedingly rare occurrence, and at the time of writing of this paper, only 15 such published
reports exist in the English literature so far.
1.Introduction
Mycobacterium tuberculosis (MTB) continues to predomi-
nate the cause of morbidity and mortality in the developing
world. The disease aﬀects all the organ systems and presents
invariouspathologicdiseasestates.Wereportanuncommon
manifestation of this rather common infectious disease in
a 19-year-old male. This case was challenging not only
due to a rare manifestation of MTB, but also because the
patient could not tolerate the classic ﬁrst-line four-drug
antituberculoustherapy(ATT)andwasmanagedwithaﬁve-
drug modiﬁed ATT.
2.CaseReport
A 19-year-old male with no known comorbidities presented
to outside hospital with a history of high-grade fever of two
weeks duration, associated with productive cough with scant
expectoration. The clinical examination was signiﬁcant for
decreased air entry on right side of the chest on auscultation,
with a stony dull percussion note. The patient had an unre-
markable complete blood count and basic metabolic panel.
Erythrocyte sedimentation rate was raised at 40mm/hour.
A chest x-ray done revealed blunting of the right costo-
phrenic angle consistent with right-fsided pleural eﬀusion.
A diagnostic thoracentesis was performed that revealed an
exudative, lymphocytic-predominant pleural ﬂuid. A clinical
diagnosis of tuberculosis involving the pleura was made, and
patient initiated on four-drug ATT with isoniazid (INH),
rifampin, pyrazinamide (PZA), and ethambutol (ETH). The
ATTwasmodiﬁedseveraltimes,asthepatienthadsigniﬁcant
side eﬀects to many drugs including PZA causing high uric
acid levels, oﬂoxacin causing severe gastrointestinal symp-
toms, streptomycin causing otologic toxicity manifesting
as vertiginous symptoms, and ethambutol causing bilateral
optic neuritis manifesting as bilateral diminution of vision,
o b j e c t i v e l yc o n ﬁ r m e db yv i s u a le v o k e dp o t e n t i a l s .W h i l e
on modiﬁed ATT, the patient had a generalized tonic-
clonic seizure. Magnetic resonance imaging (MRI) of the
brain done revealed right frontal, temporal, parietal, and
cerebellar parenchymal lesions. Antiseizure therapy with
phenytoin was initiated. A follow-up chest x-ray following
two months of ATT now revealed bilateral pleural eﬀusions.
A repeat diagnostic thoracentesis was consistent with an2 Case Reports in Medicine
exudative, lymphocytic-predominant pleural ﬂuid, with a
high adenosine deaminase (ADA) content of 135.2 (normal
<40). Bronchoscopy with bronchoalveolar lavage smear was
negative for acid fast bacilli. A transbronchial lung biopsy
showed multiple ill-deﬁned epithelioid granulomas with
inﬂammatory cell inﬁltrates.
T h ep a t i e n tw a sr e f e r r e dt ou sw i t hc o n c e r n sf o rp e r s i s -
tent moderate- to high-grade fever, cough with scant expec-
toration,worseningbilateralpleuraleﬀusions,andnewonset
epistaxis. Physical examination was signiﬁcant for a febrile,
tachycardic cachectic young male with ﬂorid petechial rash
presentoverthechestandtheanteriorabdominalwall.There
was a decreased expansion of both halves of the chest with
decreased air entry bilaterally on auscultation. Examination
of the abdomen was remarkable for hepatosplenomegaly.
Review of other systems was unremarkable. Laboratory
evaluation done revealeda low hemoglobin of 7.6g/dL, a low
platelet count of 29000/cu.mm, and deranged liver function
tests with mild elevation of aspartate (AST), and alanine
aminotransferase (ALT) (87, and 68units/L), respectively
and signiﬁcantly high alkaline phosphatase (ALP) levels
(1743 U/L). Patient had normal prothrombin time (PT) and
activated partial thromboplastin time (aPTT). Other labora-
tory investigations done to rule out other causes of persistent
fever despite adequate antituberculous therapy were all
unremarkable, that is, a normal urinalysis, negative blood,
and urine cultures, no malaria parasite on peripheral smear,
negative dengue serologies, a negative Widal agglutination
test, negative antistreptolysin O (ASO) titers, and a normal
2-dimensional echocardiogram. A contrast-enhanced com-
puted tomography (CECT) scan of the chest and abdomen
done revealed multiple miliary nodules seen throughout the
lung parenchyma bilaterally, with bilateral pleural eﬀusions,
enlarged necrotic lymph nodes in subcarinal, and right
hilar regions, multiple well-deﬁned hypodense lesions noted
in the liver, spleen, and right kidney, and large wedge-
shaped hypodense lesion in the posterior surface of lower
pole of spleen. A diagnosis of disseminated tuberculosis
was made on clinical and radiologic evidence, and previous
histopathologic data, and patient continued on modiﬁed
ATT with the following ﬁve-drug regimen: INH, PZA,
ethionamide, moxiﬂoxacin, and amikacin. Other supportive
measures were also instituted, including corticosteroids for
disseminated tuberculosis (hydrocortisone sodium succinate
50 mg intravenously thrice daily) and platelet transfusions
for a low platelet count.
The patient’s hospital course was complicated by a
persistently declining platelet count, refractory to platelet
transfusions. The peripheral smear examination revealed
thrombocytopenia. Bone marrow aspirate showed a slight
increase in megakaryocytes, consistent with megakaryocytic
thrombocytopenia. Bone biopsy revealed multiple necro-
tizing epithelioid cell granulomas with areas of diﬀuse
necrosis consistent with disseminated tuberculosis. The
patient was initiated on 1mg/kg/day of oral prednisone. The
platelet count showed rapid recovery following initiation
of immunomodulatory therapy, with a platelet count of
285000/cu.mm after a week of prednisone (Figure 1). A
close followup was maintained, and the patient successfully
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weaned from prednisone with complete recovery of platelet
count.
3. Discussion
Tuberculosis is one of the world’s most challenging commu-
nicable diseases. The hematological abnormalities associated
with tuberculosis are well recognized. Table 1 summarizes
the hematological manifestations in patients with tubercu-
losis in various studies [1].
Bone marrow changes have also been well described
in tuberculosis and include changes in marrow cellularity
manifesting as myeloid hyperplasia that occurs more com-
monly with pulmonary tuberculosis, plasmacytosis, mega-
loblasticchangesincelllineages,andmarrowaplasia.Miliary
tuberculosis is associated with histiophagocytosis of all cell
lineages and caseating granuloma formation in 60–70%
cases. Other marrow changes in tuberculosis include marrow
necrosis and myeloﬁbrosis.
Thrombocytopenia in tuberculosis can occur due to a
defect in platelet production (marrow suppression), as a
side eﬀect of anti-tuberculous therapy, histiophagocytosis
as described above, tuberculosis complicated by thrombotic
thrombocytopenicpurpura(TTP),ordisseminatedintravas-
cular coagulopathy (DIC), or due to immune-mediated
platelet destruction.
Drug-induced thrombocytopenia (i.e., as a side eﬀect
of anti-tuberculous therapy) develops within 6-7 days in
individuals taking drugs for the ﬁrst time, and within
hours in sensitized patients. Some patients may not develop
thrombocytopenia form months to years. The platelet count
is usually restored within a week of cessation of the oﬀending
agent. Corticosteroids have also been used in such scenarios,
with intravenous immune globulin (IVIg) or plasmapheresis
reserved for life-threatening situations.
Immune-mediated thrombocytopenia occurring as a
consequence of the tuberculosis infection itself is an exceed-
inglyrareoccurrence,andatthetimeofwritingofthispaper,
only 15 such published reports exist in the English literature
so far [2–16]. The immune basis of tuberculosis-induced
thrombocytopenia in these case reports is supported by the
presence of either the platelet antigen-speciﬁc antibodies
or platelet surface membrane IgG [8, 10], or by response
to immunomodulatory therapy [3, 6]. The pathogene-
sis of tuberculosis causing immune thrombocytopenia is
thought to be the generation of antiplatelet antibodies by
lymphocytes borne as a result of clonal proliferation due
to host’s immune response to the tuberculous pathogenCase Reports in Medicine 3
Table 1: Haematological manifestations in patients with tuberculosis in various studies.
No. Haematological changes Limit Pulmonary Tuberculosis (in %) Miliary Tuberculosis (in %)
1 Anemia <13g/dl in males; <11g/dl in females 16–76 52–72
2 Leucopenia <4000/ml 1.5–4 9–32
3L e u c o c y t o s i s >11000/ml
4 Lymphocytopenia <1500/ml 8–31 87–100
5 Neutrophilia >7000/ml 29–57 20–60
6 Monocytopenia 29–60 4–6
7 Thrombocytopenia <150000/ml Rare 23–42
8 Thrombocytosis >4000000/ml 52 Rare
9 Pancytopenia Rare
Reference: [1]
[10]. In our patient, this was proven by favorable response
to immunomodulatory therapy with concomitant ATT.
Antiplatelet antibodies were not done as this was not
routinely available for clinical use in India.
All the patients cited in the literature responded to
immunomodulatory therapy with concomitant ATT. The
facts that immunomodulatory therapy alone in all the
reported cases did not result in improvement and that
eﬀective concomitant ATT was needed as an adjunct support
tuberculosis as the cause for immune thrombocytopenia.
The characteristics of reported patients with immune-
mediated thrombocytopenia were as follows:
(1) Female,
(2) 3rd–8th decades of life,
(3) Middle-Eastern and Asian descent,
(4) pulmonary tuberculosis most commonly associated
(33%),
(5) disseminated tuberculosis associated in 19% of cases,
(6) tubercular lymphadenitis associated in 19% of cases.
Our case was challenging and unique in several aspects.
(1) The patient manifested with classic side eﬀects to
several ﬁrst-line agents used in ATT. Modiﬁcation of
ATT and optimization of therapy were a challenge,
and the patient successfully responded to a modiﬁed
ﬁve-drug regimen with INH, PZA, ethionamide,
moxiﬂoxacin, and amikacin.
(2) The pathology in most of the reported cases was pul-
monary tuberculosis. Our patient had tuberculosis-
related immune thrombocytopenia in the setting of
disseminated tuberculosis (19% association).
(3) While most of the cases reported in the world
literature were middle-aged females, our patient was
a young, adolescent male.
4. Conclusion
The incidence of tuberculosis continues to rise due to
evolution of bacteria resistant to anti-tuberculous agents and
spread of human immunodeﬁciency virus (HIV) worldwide.
Tuberculosis has varied manifestations, and the clinicians
must also recognize tuberculosis-mediated immune throm-
bocytopenia as a manifestation of the disease. The phe-
nomenon has also been recently reported in a child for the
ﬁrst time [15]. The pathophysiologic mechanisms behind
it remain unclear. Adherence to anti-tuberculous therapy
with initiation of immunomodulatory therapy deﬁnes the
treatment of this speciﬁc condition.
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